These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 14967028)
1. Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model. Wierdl M; Morton CL; Nguyen NK; Redinbo MR; Potter PM Biochemistry; 2004 Feb; 43(7):1874-82. PubMed ID: 14967028 [TBL] [Abstract][Full Text] [Related]
2. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791 [TBL] [Abstract][Full Text] [Related]
3. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023 [TBL] [Abstract][Full Text] [Related]
4. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the 'side door' in carboxylesterase-mediated catalysis and inhibition. Streit TM; Borazjani A; Lentz SE; Wierdl M; Potter PM; Gwaltney SR; Ross MK Biol Chem; 2008 Feb; 389(2):149-62. PubMed ID: 18163883 [TBL] [Abstract][Full Text] [Related]
7. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Khanna R; Morton CL; Danks MK; Potter PM Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276 [TBL] [Abstract][Full Text] [Related]
8. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Potter PM; Pawlik CA; Morton CL; Naeve CW; Danks MK Cancer Res; 1998 Jun; 58(12):2646-51. PubMed ID: 9635592 [TBL] [Abstract][Full Text] [Related]
9. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Potter PM; Wolverton JS; Morton CL; Wierdl M; Danks MK Cancer Res; 1998 Aug; 58(16):3627-32. PubMed ID: 9721871 [TBL] [Abstract][Full Text] [Related]
10. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148 [TBL] [Abstract][Full Text] [Related]
11. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321 [TBL] [Abstract][Full Text] [Related]
12. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229 [TBL] [Abstract][Full Text] [Related]
13. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073 [TBL] [Abstract][Full Text] [Related]
14. Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Hatfield MJ; Tsurkan L; Hyatt JL; Yu X; Edwards CC; Hicks LD; Wadkins RM; Potter PM Br J Pharmacol; 2010 Aug; 160(8):1916-28. PubMed ID: 20649590 [TBL] [Abstract][Full Text] [Related]
15. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Wierdl M; Morton CL; Weeks JK; Danks MK; Harris LC; Potter PM Cancer Res; 2001 Jul; 61(13):5078-82. PubMed ID: 11431344 [TBL] [Abstract][Full Text] [Related]
16. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172 [TBL] [Abstract][Full Text] [Related]
17. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Danks MK; Morton CL; Pawlik CA; Potter PM Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827 [TBL] [Abstract][Full Text] [Related]
20. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Senter PD; Beam KS; Mixan B; Wahl AF Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]